Wells Fargo & Company Boosts Johnson & Johnson (NYSE:JNJ) Price Target to $263.00

Johnson & Johnson (NYSE:JNJ) had its target price lifted by Wells Fargo & Company from $240.00 to $263.00 in a research note issued on Wednesday,MarketScreener reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 10.03% from the company’s current price.

Several other equities research analysts have also recently weighed in on JNJ. Daiwa Securities Group increased their target price on shares of Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research note on Thursday, January 29th. Morgan Stanley upped their price target on Johnson & Johnson from $262.00 to $267.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Loop Capital set a $220.00 price objective on Johnson & Johnson in a research report on Tuesday, January 27th. Argus upped their target price on Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.48.

Johnson & Johnson Stock Performance

JNJ opened at $239.03 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock’s 50 day moving average price is $241.58 and its two-hundred day moving average price is $216.38. The firm has a market capitalization of $575.74 billion, a P/E ratio of 21.67, a price-to-earnings-growth ratio of 2.37 and a beta of 0.34. Johnson & Johnson has a 12-month low of $146.12 and a 12-month high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Johnson & Johnson’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. State Street Corp lifted its position in shares of Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock worth $27,704,364,000 after purchasing an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co grew its stake in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the last quarter. Geode Capital Management LLC raised its position in Johnson & Johnson by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after purchasing an additional 1,738,292 shares during the last quarter. Finally, Norges Bank bought a new position in Johnson & Johnson in the 4th quarter valued at $6,924,523,000. Institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 beat and guidance lift — J&J reported $2.70 EPS vs. ~$2.68 expected and $24.06B revenue, then raised FY2026 sales and EPS outlook, which supports higher multiple and investor confidence. Johnson & Johnson Q1 2026 Earnings Call Transcript
• Positive Sentiment: Dividend raise reinforces income thesis — Board increased the quarterly payout to $1.34 (64th consecutive annual increase), supporting yield-oriented investors and reducing downside volatility. Business Wire: Dividend Increase
• Positive Sentiment: Commercial drivers: oncology and new therapies — Strong sales from Darzalex, Tremfya and Spravato (notable QoQ and YoY growth) underpin the raised outlook and signal sustainable growth beyond legacy products. Yahoo Finance: Raises 2026 Outlook
• Neutral Sentiment: Analyst commentary and sentiment — Some bullish takes argue upside (e.g., a MarketBeat piece saying a ~20% gain looks achievable), while others caution valuation vs. growth peers; watch analyst revisions post?call. MarketBeat: 20% Gain Thesis
• Neutral Sentiment: Media/broker notes highlight sector implications — J&J’s results are being read as a signal for healthcare ETFs and psychedelics peers (Spravato strength), which may amplify flows into/away from JNJ depending on broader sector moves. ETF Trends: Sector Implications
• Negative Sentiment: Profit decline, cash?flow and margin pressure — Despite top?line beats, Q1 profit fell and free cash flow reportedly declined, which raises near?term margin and cash concerns. RTTNews: Profit Down
• Negative Sentiment: Stelara decline & biosimilar risk — A steep drop in Stelara sales and ongoing biosimilar competition for legacy drugs remain a headwind and a source of uncertainty for sustaining past revenue levels. Reuters: Stelara Sales Disappoint
• Negative Sentiment: Mixed market reaction — Some coverage notes the stock initially slipped despite the beat, reflecting investor focus on margins, modest guidance details versus expectations and rotation within the sector. Investors Business Daily: Early Slip

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.